All In Biotech

Drug Trial Radar · NCT06564038

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

408

Planned (sponsor's estimate)

Start

Jan 30, 2025

Primary completion

May 20, 2030

Study completion May 20, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

Conditions

  • Chronic Lymphocytic Leukaemia
  • Small Lymphocytic Lymphoma
  • Mantle-cell Lymphoma
  • Large B-cell Lymphoma
  • B-cell Non-Hodgkin Lymphoma

Interventions

  • SurovatamigDrug

    Surovatamig will be administered as either SC injection or IV infusion.

  • Prednisone (or equivalent)Drug

    Prednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.

  • RituximabDrug

    Rituximab will be administered as IV infusion as per standard of care.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered as IV infusion as per standard of care.

  • VincristineDrug

    Vincristine will be administered as IV infusion as per standard of care.

  • DoxorubicinDrug

    Doxorubicin will be administered as IV infusion as per standard of care.

  • AcalabrutinibDrug

    Acalabrutinib will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special InterestTime frame: Up to 6 years 4 months
  2. Number of Participants with Dose Limiting Toxicity (DLTs)Time frame: Up to 2 months

Locations

66 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Hackensack, New Jersey · Recruiting

  • Research Site

    New Brunswick, New Jersey · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Charlotte, North Carolina · Not yet recruiting

  • Research Site

    Winston-Salem, North Carolina · Not yet recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

  • Research Site

    Heidelberg, Australia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Jinan, China · Withdrawn

  • Research Site

    Tianjin, China · Recruiting

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Ostrava - Poruba, Czechia · Recruiting

  • Research Site

    Prague, Czechia · Recruiting

  • Research Site

    Praha 2 - Nové Město, Czechia · Recruiting

  • Research Site

    Aalborg, Denmark · Recruiting

  • Research Site

    Aarhus N, Denmark · Recruiting

  • Research Site

    Copenhagen, Denmark · Recruiting

  • Research Site

    Odense C, Denmark · Recruiting

  • Research Site

    Clermont-Ferrand, France · Recruiting

  • Research Site

    Montpellier, France · Recruiting

  • Research Site

    Paris, France · Recruiting

  • Research Site

    Saint-Cloud, France · Recruiting

  • Research Site

    Villejuif, France · Recruiting

  • Research Site

    Cologne, Germany · Recruiting

  • Research Site

    Homburg, Germany · Not yet recruiting

  • Research Site

    Kiel, Germany · Recruiting

  • Research Site

    Mainz, Germany · Not yet recruiting

  • Research Site

    München, Germany · Recruiting

  • Research Site

    Würzburg, Germany · Recruiting

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.